|
시장보고서
상품코드
2055227
아베마시클립(Abemaciclib) 시장 : 적응별, 투여량별, 치료법별, 치료 단계별, 유통 채널별, 최종사용자별, 지역별Abemaciclib Market, By Indication, By Dosage Strength, By Therapy Type, By Line of Therapy, By Distribution Channel, By End User, By Geography |
||||||
아베마시클립 시장은 2026년에 21억 9,000만 달러로 추정되며, 2033년까지 51억 2,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 12.9%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 21억 9,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 12.90% | 2033년 시장 규모 예측 : | 51억 2,000만 달러 |
세계 아베마시클립 시장은 종양 치료제 분야에서 중요한 부문이며, 호르몬 수용체 양성, 인간 상피 성장 인자 수용체 2 음성(HR+/HER2-) 진행성 또는 전이성 유방암의 치료 패러다임에 혁명을 일으킨 선택적 사이클린 의존성 키나아제(CDK) 4/6 억제제에 초점을 맞추었습니다.
주로 일라이 릴리 앤드 컴퍼니(Eli Lilly and Company)에서 ‘베르제니오(Verzenio)’라는 이름으로 판매되고 있는 아베마시클립는 암세포의 분열을 촉진하는 특정 단백질을 억제함으로써 작용하여 종양의 진행을 효과적으로 늦추고, 환자의 무재발 생존 기간을 연장합니다. 이 화합물의 독보적인 약리학적 특성 덕분에 치료를 중단하지 않고 지속적으로 투여할 수 있어, 동일 치료 분야의 다른 CDK4/6 억제제들과는 차별화됩니다.
세계 의료 시스템이 정밀 의학 및 표적 암 치료를 우선시하는 가운데, 아베마시클립 시장은 임상 적응증 확대, 유방암 발병률 증가, 그리고 맞춤형 치료 옵션에 대한 인식 제고에 힘입어 눈부신 성장을 이루고 있습니다.
이 시장에는 제약사, 의료 서비스 제공업체, 환자, 규제 당국 등 다양한 이해관계자가 포함되어 있으며, 이들 모두가 이 혁신적인 치료제를 둘러싼 역동적인 생태계에 기여하고 있습니다. 최근 임상시험을 통해 조기 유방암의 보조 요법을 포함한 다양한 치료 환경에서 아베마시클립의 유효성이 다시 한번 입증됨에 따라 시장 잠재력이 확대되었으며, 현대 종양학 치료 프로토콜에서 핵심 치료제로서의 입지를 확고히 하고 있습니다.
시장 역학
세계 아베마시클립 시장은 성장 궤도를 지속적으로 형성하고 있는 몇 가지 주요 촉진요인에 의해 견인되고 있습니다. 그 주된 요인은 전 세계 수백만 명의 여성에게 영향을 미치며 표적 치료가 필요한 유방암의 가장 흔한 하위 유형인 호르몬 수용체 양성 유방암의 전 세계 유병률 증가입니다.
정밀 의학 접근법과 바이오마커에 기반한 치료법 선택이 확산되고 있는 것은 아베마시클립 시장 침투를 크게 촉진하고 있습니다. 이는 의료진이 환자의 예후 개선에 있어 CDK4/6 억제의 가치를 점점 더 인식하고 있기 때문입니다. 전이성 유방암의 영역을 넘어 고위험 조기 유방암에 대한 보조 요법으로 적응증을 확대함에 따라, 대상 환자층이 대폭 확대되어 새로운 수익 기회와 시장 부문이 창출되었습니다.
그러나 이 시장에는 뚜렷한 제약도 존재합니다. 높은 치료비가 신흥국에서의 접근성을 제한하고 있으며, 선진국의 의료 제도에서도 보험 적용과 관련된 문제를 야기하고 있어, 환자들이 이 혁신적인 치료법을 이용하기 어려울 수 있습니다. 설사, 호중구 감소증, 피로감 등 아베마시클리브 치료에 수반되는 중대한 부작용은 용량 조정이나 치료 중단으로 이어질 우려가 있어, 시장 성장과 환자의 복약 순응도에 영향을 미칩니다.
팔보시클리브나 리보시클리브와 같은 대체 CDK4/6 억제제와의 경쟁은 가격 압박과 시장 점유율 확보에 어려움을 초래하고 있으며, 한편으로는 특허 만료가 다가옴에 따라 제네릭 의약품에 의한 경쟁 위협도 커지고 있습니다. 이러한 과제가 있음에도 불구하고, 다른 표적 치료제나 면역요법과의 병용 요법에서 적응증 확대라는 형태로 큰 기회가 존재하며, 치료 효과를 높이는 시너지 효과를 발휘하는 치료 요법의 구축이 기대됩니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 시장 성장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음 매개변수를 바탕으로 전 세계 아베마시클리브 시장의 주요 기업 프로파일을 작성했습니다. 기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적 및 전략.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 세계의 아베마시클립 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 아베마시클리브 시장을 분석하는 데 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 아베마시클립 시장 : 적응증별, 2021년-2033년
제5장 세계의 아베마시클립 시장 : 투여량별, 2021년-2033년
제6장 세계의 아베마시클립 시장 : 요법 유형별, 2021년-2033년
제7장 세계의 아베마시클립 시장 : 치료 단계별, 2021년-2033년
제8장 세계의 아베마시클립 시장 : 유통 채널별, 2021년-2033년
제9장 세계의 아베마시클립 시장 : 최종사용자별, 2021년-2033년
제10장 세계의 아베마시클립 시장 : 지역별, 2021년-2033년
제11장 경쟁 구도
제12장 애널리스트의 제안
제13장 참고 문헌 및 조사 방법
LSH 26.06.22Abemaciclib Market is estimated to be valued at USD 2.19 Bn in 2026 and is expected to reach USD 5.12 Bn by 2033, growing at a compound annual growth rate (CAGR) of 12.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.19 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 12.90% | 2033 Value Projection: | USD 5.12 Bn |
The global Abemaciclib market represents a critical segment within the oncology therapeutics landscape, focusing on a selective cyclin-dependent kinase (CDK) 4/6 inhibitor that has revolutionized treatment paradigms for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer.
Abemaciclib, marketed primarily as Verzenio by Eli Lilly and Company, functions by blocking specific proteins that promote cancer cell division, effectively slowing tumor progression and extending progression-free survival in patients. The compound's unique pharmacological profile allows for continuous dosing without treatment breaks, distinguishing it from other CDK4/6 inhibitors in the therapeutic class.
As healthcare systems worldwide prioritize precision medicine and targeted cancer therapies, the Abemaciclib market has experienced substantial growth driven by expanding clinical applications, increasing breast cancer incidence rates, and growing awareness of personalized treatment options.
The market encompasses various stakeholders including pharmaceutical manufacturers, healthcare providers, patients, and regulatory bodies, all contributing to the dynamic ecosystem surrounding this innovative therapeutic agent. Recent clinical trials have further validated Abemaciclib's efficacy across different treatment settings, including adjuvant therapy for early-stage breast cancer, thereby expanding its market potential and positioning it as a cornerstone therapy in modern oncology treatment protocols.
Market Dynamics
The global Abemaciclib market is propelled by several key drivers that continue to shape its growth trajectory, with the primary catalyst being the rising global incidence of hormone receptor-positive breast cancer, which affects millions of women worldwide and represents the most common subtype of breast cancer requiring targeted therapeutic interventions.
The increasing adoption of precision medicine approaches and biomarker-driven treatment selection has significantly enhanced Abemaciclib's market penetration, as healthcare providers increasingly recognize the value of CDK4/6 inhibition in improving patient outcomes. Expanding clinical indications beyond metastatic settings to include adjuvant therapy for high-risk early-stage breast cancer has substantially broadened the addressable patient population, creating new revenue opportunities and market segments.
However, the market faces notable restraints including the high cost of treatment that limits accessibility in emerging economies and creates reimbursement challenges even in developed healthcare systems, potentially restricting patient access to this innovative therapy. Significant side effects associated with Abemaciclib treatment, including diarrhea, neutropenia, and fatigue, can lead to dose modifications or treatment discontinuation, impacting market growth and patient compliance rates.
Competition from alternative CDK4/6 inhibitors such as palbociclib and ribociclib creates pricing pressure and market share challenges, while generic competition threats loom as patents approach expiration. Despite these challenges, substantial opportunities exist in the form of expanding applications in combination therapies with other targeted agents and immunotherapies, potentially creating synergistic treatment regimens that could enhance efficacy outcomes.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Abemaciclib market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Eli Lilly and Company, Pfizer Inc, Novartis AG, AstraZeneca plc, Roche Holding AG, Sanofi, Merck and Co Inc, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Bayer AG, GlaxoSmithKline plc, Johnson and Johnson, BeiGene Ltd, Eisai Co Ltd, and Jiangsu Hengrui Pharmaceuticals Co Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Abemaciclib market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Abemaciclib market
Market Segmentation
- Indication Insights (Revenue, USD Bn, 2021 - 2033)
- Early Breast Cancer (HR-positive, HER2-negative)
- Advanced or Metastatic Breast Cancer (HR-positive, HER2-negative)
- Other Cancer Types (e.g., Lung Cancer, under research or off-label use)
- Dosage Strength Insights (Revenue, USD Bn, 2021 - 2033)
- 50 mg
- 100 mg
- 150 mg
- 200 mg
- Therapy Type Insights (Revenue, USD Bn, 2021 - 2033)
- Monotherapy (Abemaciclib alone)
- Combination Therapy (with endocrine therapy, other cancer drugs)
- Line of Therapy Insights (Revenue, USD Bn, 2021 - 2033)
- First-line endocrine-based treatment
- Second-line after progression on prior endocrine therapy
- Third-line and later after chemotherapy
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Academic oncology centers
- Comprehensive cancer hospitals
- Private oncology clinics
- Government/public hospitals
- Others (home care)
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Eli Lilly and Company
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Abemaciclib Market, By Indication
- Global Abemaciclib Market, By Dosage Strength
- Global Abemaciclib Market, By Therapy Type
- Global Abemaciclib Market, By Line of Therapy
- Global Abemaciclib Market, By Distribution Channel
- Global Abemaciclib Market, By End User
- Global Abemaciclib Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Abemaciclib Market, By Indication, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Early Breast Cancer (HR-positive, HER2-negative)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Advanced or Metastatic Breast Cancer (HR-positive, HER2-negative)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Other Cancer Types (e.g., Lung Cancer, under research or off-label use)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Abemaciclib Market, By Dosage Strength, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- 50 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- 100 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- 150 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- 200 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Abemaciclib Market, By Therapy Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Monotherapy (Abemaciclib alone)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Combination Therapy (with endocrine therapy, other cancer drugs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Abemaciclib Market, By Line of Therapy, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- First-line endocrine-based treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Second-line after progression on prior endocrine therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Third-line and later after chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Abemaciclib Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Hospital pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Abemaciclib Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Academic oncology centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Comprehensive cancer hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Private oncology clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Government/public hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (home care)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Abemaciclib Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Line of Therapy , 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Line of Therapy , 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Line of Therapy , 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Line of Therapy , 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Line of Therapy , 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Line of Therapy , 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
